Clinical Insights in Renal Cell Carcinoma
VIDEO: Belzutifan plus cabozantinib potential treatment for advanced renal cell carcinoma
Transcript
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
We also just saw the presentation of LITESPARK-003. So this is a phase 2 trial of adding belzutifan to cabozantinib, so two mechanisms of action: belzutifan hitting HIF-2 alpha, cabozantinib hitting VEGF receptors, as well as MET and AXL. And we saw in treatment naive population a really nice, objective response rate, around 70%, and in the pretreated cohorts also some good responses, but not quite 70%, as the cohort 1. There are multiple trials ongoing now that are combining belzutifan in the frontline setting and even earlier in the adjuvant setting. And so, the belzutifan-cabozantinib data really set that up very well for further combination strategies.MADRID —Tian Zhang, MD, discussed the positive results presented at ESMO Congress on use of belzutifan combined with cabozantinib for patients with advanced clear cell renal cell carcinoma.
The phase 2 LITESPARK-003 study looked at the HIF-2alpha inhibitor belzutifan (Welireg, Merck) combined with the VEGF receptor cabozantinib (Cabometyx, Exelixis) in patients with no prior systemic therapy for advanced renal cell carcinoma, and those who had received prior immunotherapy and two or more systemic regimens.
Watch more in RCC
There was a “really nice objective response rate of around 70%” observed in the treatment-naive population and good responses in the pretreated population, according to Zhang, genitourinary oncologist at UT Southwestern Medical Center and member of the Kidney Cancer Association's Medical Steering Committee.
“There are multiple trials ongoing now that are combining belzutifan in the front-line setting and even earlier in the adjuvant setting. So, the belzutifan and cabozantinib data really set that up very well for further combination strategies,” Zhang said.
Reference:
- Choueiri TK, et al. Abstract LBA87. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Click Here to Manage Email Alerts
